{"transactions":[{"id":312322,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":1725,"price":496.95,"value":857238.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17)."}],"balance_after":98278,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312321,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":5995,"price":496.16,"value":2974479.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74)."}],"balance_after":100003,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312320,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":15580,"price":495.38,"value":7718020.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78)."}],"balance_after":105998,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312319,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":3498,"price":494.33,"value":1729166.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75)."}],"balance_after":121578,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312318,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2520,"price":493.29,"value":1243090.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77)."}],"balance_after":125076,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312317,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":949,"price":491.3,"value":466243.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85)."}],"balance_after":127596,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312316,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2725,"price":490.54,"value":1336721.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01)."}],"balance_after":128545,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312315,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":460,"price":489.32,"value":225087.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79)."}],"balance_after":131270,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312314,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":3278,"price":488.27,"value":1600549.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56)."}],"balance_after":131730,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312313,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2510,"price":487.13,"value":1222696.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $487.13  (range $486.64 to $487.55)."}],"balance_after":135008,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312312,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":240,"price":482.84,"value":115881.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85)."}],"balance_after":137518,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312311,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":120,"price":481.5,"value":57780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51)."}],"balance_after":137758,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312310,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":400,"price":479.75,"value":191900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76)."}],"balance_after":137878,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312727,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-26T23:09:50.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":4981,"price":485.11,"value":2416332.91,"ownership":{"direct":true},"balance_after":138278,"source":{"system":"sec-edgar","filing":"0000875320-26-000114","document":"wk-form4_1772147388.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000114/wk-form4_1772147388.xml","form_type":"4"}},{"id":313139,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-19T21:16:37.000Z","date":"2026-02-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":6554,"price":483.75,"value":3170497.5,"ownership":{"direct":true},"balance_after":143259,"source":{"system":"sec-edgar","filing":"0000875320-26-000090","document":"wk-form4_1771535794.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000090/wk-form4_1771535794.xml","form_type":"4"}},{"id":313138,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-19T21:16:37.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":16326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":149813,"source":{"system":"sec-edgar","filing":"0000875320-26-000090","document":"wk-form4_1771535794.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000090/wk-form4_1771535794.xml","form_type":"4"}},{"id":313475,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-18T21:35:20.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":13041,"price":487.76,"value":6360878.16,"ownership":{"direct":true},"balance_after":133487,"source":{"system":"sec-edgar","filing":"0000875320-26-000070","document":"wk-form4_1771450516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000070/wk-form4_1771450516.xml","form_type":"4"}},{"id":313862,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-12T22:00:16.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":8297,"price":468.41,"value":3886397.77,"ownership":{"direct":true},"balance_after":146528,"source":{"system":"sec-edgar","filing":"0000875320-26-000046","document":"wk-form4_1770933613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000046/wk-form4_1770933613.xml","form_type":"4"}},{"id":314832,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-01-26T21:25:45.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":11885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":154825,"source":{"system":"sec-edgar","filing":"0000875320-26-000018","document":"wk-form4_1769462741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000018/wk-form4_1769462741.xml","form_type":"4"}},{"id":314831,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-01-26T21:25:45.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":26972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":142940,"source":{"system":"sec-edgar","filing":"0000875320-26-000018","document":"wk-form4_1769462741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000018/wk-form4_1769462741.xml","form_type":"4"}},{"id":320076,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-08-07T20:23:31.000Z","date":"2025-08-06","kind":"purchase","planned":false,"acquired":true,"shares":5710,"price":389.95,"value":2226614.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53)."}],"balance_after":115968,"source":{"system":"sec-edgar","filing":"0000875320-25-000220","document":"wk-form4_1754598207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000220/wk-form4_1754598207.xml","form_type":"4"}},{"id":320075,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-08-07T20:23:31.000Z","date":"2025-08-06","kind":"purchase","planned":false,"acquired":true,"shares":4290,"price":389.08,"value":1669153.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."}],"balance_after":110258,"source":{"system":"sec-edgar","filing":"0000875320-25-000220","document":"wk-form4_1754598207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000220/wk-form4_1754598207.xml","form_type":"4"}},{"id":325021,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-28T21:43:53.000Z","date":"2025-02-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":14079,"price":479.61,"value":6752429.19,"ownership":{"direct":true},"balance_after":105915,"source":{"system":"sec-edgar","filing":"0000875320-25-000131","document":"wk-form4_1740779025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000131/wk-form4_1740779025.xml","form_type":"4"}},{"id":325177,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-26T21:12:32.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":9386,"price":483.28,"value":4536066.08,"ownership":{"direct":true},"balance_after":119994,"source":{"system":"sec-edgar","filing":"0000875320-25-000111","document":"wk-form4_1740604345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000111/wk-form4_1740604345.xml","form_type":"4"}},{"id":325783,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-19T21:31:55.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":6553,"price":463.46,"value":3037053.38,"ownership":{"direct":true},"balance_after":129380,"source":{"system":"sec-edgar","filing":"0000875320-25-000089","document":"wk-form4_1740000707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000089/wk-form4_1740000707.xml","form_type":"4"}},{"id":326068,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-14T21:13:22.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":19015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":135933,"source":{"system":"sec-edgar","filing":"0000875320-25-000067","document":"wk-form4_1739567593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000067/wk-form4_1739567593.xml","form_type":"4"}},{"id":326169,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-12T21:46:06.000Z","date":"2025-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":8300,"price":467.98,"value":3884234.0,"ownership":{"direct":true},"balance_after":116918,"source":{"system":"sec-edgar","filing":"0000875320-25-000044","document":"wk-form4_1739396757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000044/wk-form4_1739396757.xml","form_type":"4"}},{"id":326552,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-06T21:37:40.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":20328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":125218,"source":{"system":"sec-edgar","filing":"0000875320-25-000018","document":"wk-form4_1738877851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000018/wk-form4_1738877851.xml","form_type":"4"}},{"id":326551,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-06T21:37:40.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":29118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":104890,"source":{"system":"sec-edgar","filing":"0000875320-25-000018","document":"wk-form4_1738877851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000018/wk-form4_1738877851.xml","form_type":"4"}},{"id":329512,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-11-12T21:08:32.000Z","date":"2024-11-08","kind":"sale","planned":true,"acquired":false,"shares":15198,"price":515,"value":7826970.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024."}],"balance_after":75772,"source":{"system":"sec-edgar","filing":"0000875320-24-000225","document":"wk-form4_1731445703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000225/wk-form4_1731445703.xml","form_type":"4"}},{"id":331721,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-08-01T20:17:25.000Z","date":"2024-07-30","kind":"sale","planned":true,"acquired":false,"shares":15202,"price":505,"value":7677010.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024."}],"balance_after":90970,"source":{"system":"sec-edgar","filing":"0000875320-24-000195","document":"wk-form4_1722543438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000195/wk-form4_1722543438.xml","form_type":"4"}},{"id":331920,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-07-24T20:05:44.000Z","date":"2024-07-22","kind":"sale","planned":true,"acquired":false,"shares":15202,"price":497,"value":7555394.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024."}],"balance_after":106172,"source":{"system":"sec-edgar","filing":"0000875320-24-000187","document":"wk-form4_1721851538.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000187/wk-form4_1721851538.xml","form_type":"4"}},{"id":1478417,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-14T16:24:07.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":false,"shares":105263,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":105263},"source":{"system":"sec-edgar","filing":"0001127602-24-018713","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000112760224018713/form4.xml","form_type":"4"}},{"id":1478416,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true}}],"security":"Class A Common Stock","published_at":"2024-06-14T16:24:07.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":true,"shares":105263,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."}],"balance_after":186002,"source":{"system":"sec-edgar","filing":"0001127602-24-018713","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000112760224018713/form4.xml","form_type":"4"}},{"id":333305,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T20:08:32.000Z","date":"2024-05-24","kind":"exercise","planned":true,"acquired":false,"shares":1565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":1565},"source":{"system":"sec-edgar","filing":"0000875320-24-000160","document":"wk-form4_1717013304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000160/wk-form4_1717013304.xml","form_type":"4"}},{"id":333304,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-05-29T20:08:32.000Z","date":"2024-05-24","kind":"sale","planned":true,"acquired":false,"shares":1565,"price":457,"value":715205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024."}],"balance_after":121374,"source":{"system":"sec-edgar","filing":"0000875320-24-000160","document":"wk-form4_1717013304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000160/wk-form4_1717013304.xml","form_type":"4"}},{"id":333303,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-05-29T20:08:32.000Z","date":"2024-05-24","kind":"exercise","planned":true,"acquired":true,"shares":1565,"price":187.53,"value":293484.45,"ownership":{"direct":true},"balance_after":122939,"source":{"system":"sec-edgar","filing":"0000875320-24-000160","document":"wk-form4_1717013304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000160/wk-form4_1717013304.xml","form_type":"4"}},{"id":333468,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-05-22T20:21:45.000Z","date":"2024-05-20","kind":"sale","planned":true,"acquired":false,"shares":15202,"price":447,"value":6795294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024."}],"balance_after":121374,"source":{"system":"sec-edgar","filing":"0000875320-24-000156","document":"wk-form4_1716409296.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000156/wk-form4_1716409296.xml","form_type":"4"}},{"id":339122,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-27T21:55:24.000Z","date":"2024-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":9386,"price":431.79,"value":4052780.94,"ownership":{"direct":true},"balance_after":136507,"source":{"system":"sec-edgar","filing":"0000875320-24-000105","document":"wk-form4_1709070906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000105/wk-form4_1709070906.xml","form_type":"4"}},{"id":339693,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-21T21:29:46.000Z","date":"2024-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":7019,"price":420.58,"value":2952051.02,"ownership":{"direct":true},"balance_after":145893,"source":{"system":"sec-edgar","filing":"0000875320-24-000074","document":"wk-form4_1708550975.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000074/wk-form4_1708550975.xml","form_type":"4"}},{"id":339692,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-21T21:29:46.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":9359,"price":424.01,"value":3968309.59,"ownership":{"direct":true},"balance_after":152912,"source":{"system":"sec-edgar","filing":"0000875320-24-000074","document":"wk-form4_1708550975.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000074/wk-form4_1708550975.xml","form_type":"4"}},{"id":340495,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-13T22:07:28.000Z","date":"2024-02-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":8255,"price":422.74,"value":3489718.7,"ownership":{"direct":true},"balance_after":162271,"source":{"system":"sec-edgar","filing":"0000875320-24-000051","document":"wk-form4_1707862030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000051/wk-form4_1707862030.xml","form_type":"4"}},{"id":341074,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-08T21:38:01.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":20327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":170526,"source":{"system":"sec-edgar","filing":"0000875320-24-000026","document":"wk-form4_1707428268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000026/wk-form4_1707428268.xml","form_type":"4"}},{"id":341073,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-08T21:38:01.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":26972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":150199,"source":{"system":"sec-edgar","filing":"0000875320-24-000026","document":"wk-form4_1707428268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000026/wk-form4_1707428268.xml","form_type":"4"}},{"id":341072,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-02-08T21:38:01.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":14516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":123227,"source":{"system":"sec-edgar","filing":"0000875320-24-000026","document":"wk-form4_1707428268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000026/wk-form4_1707428268.xml","form_type":"4"}},{"id":343470,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T21:15:42.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":false,"shares":14077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":1565,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":14077},"source":{"system":"sec-edgar","filing":"0000875320-23-000062","document":"wk-form4_1703020525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000062/wk-form4_1703020525.xml","form_type":"4"}},{"id":343469,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T21:15:42.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":false,"shares":3058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":3058},"source":{"system":"sec-edgar","filing":"0000875320-23-000062","document":"wk-form4_1703020525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000062/wk-form4_1703020525.xml","form_type":"4"}},{"id":343468,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-12-19T21:15:42.000Z","date":"2023-12-15","kind":"sale","planned":true,"acquired":false,"shares":17135,"price":407,"value":6973945.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023."}],"balance_after":108711,"source":{"system":"sec-edgar","filing":"0000875320-23-000062","document":"wk-form4_1703020525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000062/wk-form4_1703020525.xml","form_type":"4"}},{"id":343467,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-12-19T21:15:42.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":true,"shares":14077,"price":187.53,"value":2639859.81,"ownership":{"direct":true},"balance_after":125846,"source":{"system":"sec-edgar","filing":"0000875320-23-000062","document":"wk-form4_1703020525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000062/wk-form4_1703020525.xml","form_type":"4"}},{"id":343466,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-12-19T21:15:42.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":true,"shares":3058,"price":155.57,"value":475733.06,"ownership":{"direct":true},"balance_after":111769,"source":{"system":"sec-edgar","filing":"0000875320-23-000062","document":"wk-form4_1703020525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000062/wk-form4_1703020525.xml","form_type":"4"}},{"id":343618,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-12-15T21:23:03.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":5098,"price":397,"value":2023906.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023."}],"balance_after":108711,"source":{"system":"sec-edgar","filing":"0000875320-23-000058","document":"wk-form4_1702675367.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000058/wk-form4_1702675367.xml","form_type":"4"}},{"id":344472,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-11-15T21:16:04.000Z","date":"2023-11-13","kind":"sale","planned":true,"acquired":false,"shares":5097,"price":377,"value":1921569.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023."}],"balance_after":113809,"source":{"system":"sec-edgar","filing":"0000875320-23-000035","document":"wk-form4_1700082955.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000035/wk-form4_1700082955.xml","form_type":"4"}},{"id":347487,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-07-18T20:13:37.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":7828,"price":355,"value":2778940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022."}],"balance_after":118906,"source":{"system":"sec-edgar","filing":"0001209191-23-042557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123042557/doc4.xml","form_type":"4"}},{"id":1847426,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true}}],"security":"Stock Option","published_at":"2023-06-21T17:07:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":139860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000."}],"balance_after":139860,"derivative":{"exercise_price":1.9,"expiration_date":"2033-06-16","underlying":"Class A Common Stock","underlying_shares":139860},"source":{"system":"sec-edgar","filing":"0001127602-23-019171","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000112760223019171/form4.xml","form_type":"4"}},{"id":1847425,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-21T17:07:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":105263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.  The RSUs have no expiration date.  RSUs granted on June 10, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated June 13, 2022 vested in full in shares on June 10, 2023."}],"balance_after":105263,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":105263},"source":{"system":"sec-edgar","filing":"0001127602-23-019171","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000112760223019171/form4.xml","form_type":"4"}},{"id":349611,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-05-01T20:26:35.000Z","date":"2023-04-27","kind":"sale","planned":true,"acquired":false,"shares":38,"price":340.19,"value":12927.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022."}],"balance_after":126652,"source":{"system":"sec-edgar","filing":"0001209191-23-026270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123026270/doc4.xml","form_type":"4"}},{"id":349610,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-05-01T20:26:35.000Z","date":"2023-04-27","kind":"sale","planned":true,"acquired":false,"shares":1668,"price":339.43,"value":566169.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98)."}],"balance_after":126690,"source":{"system":"sec-edgar","filing":"0001209191-23-026270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123026270/doc4.xml","form_type":"4"}},{"id":349609,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-05-01T20:26:35.000Z","date":"2023-04-27","kind":"sale","planned":true,"acquired":false,"shares":1611,"price":338.69,"value":545629.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99)."}],"balance_after":128358,"source":{"system":"sec-edgar","filing":"0001209191-23-026270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123026270/doc4.xml","form_type":"4"}},{"id":352329,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-28T21:53:32.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":9386,"price":289.12,"value":2713680.32,"ownership":{"direct":true},"balance_after":129969,"source":{"system":"sec-edgar","filing":"0001209191-23-013718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013718/doc4.xml","form_type":"4"}},{"id":352891,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-22T21:35:32.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":9359,"price":292.85,"value":2740783.15,"ownership":{"direct":true},"balance_after":139355,"source":{"system":"sec-edgar","filing":"0001209191-23-011686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011686/doc4.xml","form_type":"4"}},{"id":353530,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-14T21:58:03.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":5990,"price":298.26,"value":1786577.4,"ownership":{"direct":true},"balance_after":148714,"source":{"system":"sec-edgar","filing":"0001209191-23-009198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009198/doc4.xml","form_type":"4"}},{"id":353529,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-14T21:58:03.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":3372,"price":294.33,"value":992480.76,"ownership":{"direct":true},"balance_after":154704,"source":{"system":"sec-edgar","filing":"0001209191-23-009198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009198/doc4.xml","form_type":"4"}},{"id":354155,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-03T21:48:58.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":26972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":158076,"source":{"system":"sec-edgar","filing":"0001209191-23-006946","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006946/doc4.xml","form_type":"4"}},{"id":354154,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-03T21:48:58.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":29118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":131104,"source":{"system":"sec-edgar","filing":"0001209191-23-006946","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006946/doc4.xml","form_type":"4"}},{"id":354153,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-02-03T21:48:58.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":12388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":101986,"source":{"system":"sec-edgar","filing":"0001209191-23-006946","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006946/doc4.xml","form_type":"4"}},{"id":354488,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2023-01-27T21:13:21.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":10000,"price":315.05,"value":3150500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $315.05 (range $315.00 to $315.23)."}],"balance_after":89598,"source":{"system":"sec-edgar","filing":"0001209191-23-005219","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123005219/doc4.xml","form_type":"4"}},{"id":2119700,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-11-10T17:30:27.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":9818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Class A common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion of restricted stock units (\"RSUs\") into Class A common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In accordance with an agreement between the Reporting Person and the issuer to delay vesting of the RSUs, the RSUs vested on September 30, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with an agreement between the Reporting Person and the issuer to delay vesting of the RSUs, the RSUs vested on September 30, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of Class A common stock."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":9818},"source":{"system":"sec-edgar","filing":"0000899243-22-035555","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924322035555/doc4.xml","form_type":"4"}},{"id":2119699,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-11-10T17:30:27.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":9818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion of restricted stock units (\"RSUs\") into Class A common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the conversion of restricted stock units (\"RSUs\") into Class A common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the conversion of restricted stock units (\"RSUs\") into Class A common stock."}],"balance_after":80739,"source":{"system":"sec-edgar","filing":"0000899243-22-035555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924322035555/doc4.xml","form_type":"4"}},{"id":358712,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-08-17T21:40:28.000Z","date":"2022-08-15","kind":"sale","acquired":false,"shares":11689,"price":305.06,"value":3565846.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $305.06 (range $305.00 to $305.22)."}],"balance_after":99598,"source":{"system":"sec-edgar","filing":"0000899243-22-029032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322029032/doc4.xml","form_type":"4"}},{"id":360088,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-06-28T20:05:20.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":11689,"price":291.3,"value":3405005.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49)."}],"balance_after":111153,"source":{"system":"sec-edgar","filing":"0000899243-22-024385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322024385/doc4.xml","form_type":"4"}},{"id":2233594,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-13T21:12:34.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":108516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In accordance with the Non-Employee Director Compensation Policy of the Issuer, the Black-Scholes value of the option award as of the grant date is $200,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date."}],"balance_after":108516,"derivative":{"exercise_price":2.82,"expiration_date":"2032-06-10","underlying":"Class A Common Stock","underlying_shares":108516},"source":{"system":"sec-edgar","filing":"0000899243-22-022285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924322022285/doc4.xml","form_type":"4"}},{"id":2233593,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-13T21:12:34.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":70921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The vesting date of the restricted stock units and stock options, and in the case of the stock options, the exercise date, will be the earlier of either June 10, 2023 or the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date."}],"balance_after":70921,"source":{"system":"sec-edgar","filing":"0000899243-22-022285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924322022285/doc4.xml","form_type":"4"}},{"id":365012,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-28T22:21:31.000Z","date":"2022-02-24","kind":"tax_withholding","acquired":false,"shares":7246,"price":227.86,"value":1651073.56,"ownership":{"direct":true},"balance_after":122842,"source":{"system":"sec-edgar","filing":"0000899243-22-008116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008116/doc4.xml","form_type":"4"}},{"id":365564,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-22T21:56:27.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":8584,"price":232.51,"value":1995865.84,"ownership":{"direct":true},"balance_after":130088,"source":{"system":"sec-edgar","filing":"0000899243-22-007208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007208/doc4.xml","form_type":"4"}},{"id":366087,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-14T21:16:49.000Z","date":"2022-02-10","kind":"tax_withholding","acquired":false,"shares":3031,"price":237.74,"value":720589.94,"ownership":{"direct":true},"balance_after":138672,"source":{"system":"sec-edgar","filing":"0001209191-22-009236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122009236/doc4.xml","form_type":"4"}},{"id":366672,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-03T21:17:17.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":29117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/24/2023."}],"balance_after":141703,"source":{"system":"sec-edgar","filing":"0001209191-22-006775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006775/doc4.xml","form_type":"4"}},{"id":366671,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-03T21:17:17.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":29032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022."}],"balance_after":112586,"source":{"system":"sec-edgar","filing":"0001209191-22-006775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006775/doc4.xml","form_type":"4"}},{"id":366670,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2022-02-03T21:17:17.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":9800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022."}],"balance_after":83554,"source":{"system":"sec-edgar","filing":"0001209191-22-006775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006775/doc4.xml","form_type":"4"}},{"id":2496995,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-11-23T17:00:17.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":9818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (the \"RSU\") represents a contingent right to receive one share of the Issuer's Class A common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest on the day immediately prior to the Issuer's next annual meeting of shareholders and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest on the day immediately prior to the Issuer's next annual meeting of shareholders and have no expiration date."}],"balance_after":9818,"derivative":{"underlying":"Class A Common Stock","underlying_shares":9818},"source":{"system":"sec-edgar","filing":"0000899243-21-045805","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924321045805/doc4.xml","form_type":"4"}},{"id":2563660,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-09-20T21:51:13.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":17649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests on the earlier of either September 16, 2022 or the day before the Issuer's next annual meeting of stockholders."}],"balance_after":17649,"derivative":{"exercise_price":11.42,"expiration_date":"2031-09-15","underlying":"Class A Common Stock","underlying_shares":17649},"source":{"system":"sec-edgar","filing":"0000899243-21-036687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924321036687/doc4.xml","form_type":"4"}},{"id":2563659,"issuer":{"id":5530,"kind":"organization","name":"Ginkgo Bioworks Holdings, Inc.","symbol":"DNA"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-09-20T21:51:13.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":51782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three substantially equal annual installments beginning on September 16, 2022."}],"balance_after":51782,"derivative":{"exercise_price":11.42,"expiration_date":"2031-09-15","underlying":"Class A Common Stock","underlying_shares":51782},"source":{"system":"sec-edgar","filing":"0000899243-21-036687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735944/000089924321036687/doc4.xml","form_type":"4"}},{"id":372143,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-08-23T12:30:57.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":4243,"price":196.34,"value":833070.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58)."}],"balance_after":73754,"source":{"system":"sec-edgar","filing":"0001209191-21-052881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121052881/doc4.xml","form_type":"4"}},{"id":372142,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-08-23T12:30:57.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":5757,"price":195.14,"value":1123420.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."}],"balance_after":69511,"source":{"system":"sec-edgar","filing":"0001209191-21-052881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121052881/doc4.xml","form_type":"4"}},{"id":379384,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-26T21:15:48.000Z","date":"2021-02-24","kind":"tax_withholding","acquired":false,"shares":2898,"price":217.57,"value":630517.86,"ownership":{"direct":true},"balance_after":63643,"source":{"system":"sec-edgar","filing":"0001209191-21-014723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121014723/doc4.xml","form_type":"4"}},{"id":379879,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-19T21:12:30.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":2080,"price":211.75,"value":440440.0,"ownership":{"direct":true},"balance_after":66541,"source":{"system":"sec-edgar","filing":"0001209191-21-012334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121012334/doc4.xml","form_type":"4"}},{"id":380490,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-12T21:07:53.000Z","date":"2021-02-10","kind":"tax_withholding","acquired":false,"shares":2962,"price":214.16,"value":634341.92,"ownership":{"direct":true},"balance_after":68621,"source":{"system":"sec-edgar","filing":"0001209191-21-010098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121010098/doc4.xml","form_type":"4"}},{"id":380803,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-05T21:48:53.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":29031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2022."}],"balance_after":71583,"source":{"system":"sec-edgar","filing":"0001209191-21-008121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008121/doc4.xml","form_type":"4"}},{"id":380802,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-05T21:48:53.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":12388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021."}],"balance_after":42552,"source":{"system":"sec-edgar","filing":"0001209191-21-008121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008121/doc4.xml","form_type":"4"}},{"id":380801,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2021-02-05T21:48:53.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":3516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021."}],"balance_after":30164,"source":{"system":"sec-edgar","filing":"0001209191-21-008121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008121/doc4.xml","form_type":"4"}},{"id":387457,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"exercise","acquired":false,"shares":509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in 16 quarterly installments from 02/06/2018."}],"balance_after":3058,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":509},"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387456,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"exercise","acquired":false,"shares":1564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in 16 quarterly installments from 02/06/2019."}],"balance_after":15642,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":1564},"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387455,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"sale","acquired":false,"shares":93,"price":273.27,"value":25414.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."}],"balance_after":26626,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387454,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"sale","acquired":false,"shares":487,"price":272.76,"value":132834.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.25 to $272.99)."}],"balance_after":26719,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387453,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"sale","acquired":false,"shares":471,"price":271.42,"value":127838.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $271.42 (range $270.97 to $271.88)."}],"balance_after":27206,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387452,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"sale","acquired":false,"shares":870,"price":270.36,"value":235213.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $270.36 (range $269.90 to $270.85)."}],"balance_after":27677,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387451,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"sale","acquired":false,"shares":152,"price":269.11,"value":40904.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $269.11 (range $268.69 to $269.59)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":28547,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387450,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"exercise","acquired":true,"shares":509,"price":155.57,"value":79185.13,"ownership":{"direct":true},"balance_after":28699,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":387449,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-08-10T20:19:44.000Z","date":"2020-08-06","kind":"exercise","acquired":true,"shares":1564,"price":187.53,"value":293296.92,"ownership":{"direct":true},"balance_after":28190,"source":{"system":"sec-edgar","filing":"0001209191-20-045935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120045935/doc4.xml","form_type":"4"}},{"id":390313,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-05-19T20:35:24.000Z","date":"2020-05-15","kind":"sale","acquired":false,"shares":9,"price":288.37,"value":2595.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Open market sales reported on this line occurred at a weighted average price of $288.37 (range $288.23 to $288.47)."}],"balance_after":26626,"source":{"system":"sec-edgar","filing":"0001209191-20-030498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120030498/doc4.xml","form_type":"4"}},{"id":390312,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2020-05-19T20:35:24.000Z","date":"2020-05-15","kind":"sale","acquired":false,"shares":19,"price":287.63,"value":5464.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $287.63 (range $287.18 to $288.10)."}],"balance_after":26635,"source":{"system":"sec-edgar","filing":"0001209191-20-030498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120030498/doc4.xml","form_type":"4"}}],"next_cursor":"2020-05-19T20:35:24.000000Z,390312"}